Medicalsystem Biotechnology Co (300439) Fair Value & Analysis

Healthcare · CN · Market cap 3.3B CNY

Analysis

Medicalsystem Biotechnology Co (300439) currently trades at ¥8.34, while our model-based Fair Value estimate is ¥3.80 — implying the stock looks roughly 54.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Medicalsystem Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products in China. It is also involved in the provision of Three-party medical diagnosis services. The company offers automated chemistry analyzers; and automated chemiluminescence immunoassay analyzer; hematology analyzers and reagents; total laboratory automation system; mass spectrometry; and, blood lipid subfraction analyzer, and POCT.It also provides healthcare services. Medicalsystem Biotechnology Co., Ltd. was formerly known as Ningbo Medicalsystem Biotechnology Co., Ltd. and changed its name to Biotechnology Co., Ltd. in January 2017. Medicalsystem Biotechnology Co., Ltd. was founded in 2003 and is based in Ningbo, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.